On Friday morning, both A-Shares and Hong Kong shares are now adjusted.
In terms of a shares, the main indexes fell further, with the gem and the science and technology innovation board leading the decline.
The “seesaw” effect of the market reappeared, tourism stocks broke out collectively, the covid-19 detection concept fell collectively, and many stocks fell by the “20cm” limit.
In terms of individual stocks, “northeast yaomao” Changchun High And New Technology Industries (Group) Inc(000661) fell by the limit for three consecutive trading days.
Hong Kong stocks adjusted slightly after yesterday’s sharp rise. In the past Thursday, the Hang Seng Index of Hong Kong stocks rose as high as 3.42% throughout the day, the largest one-day increase in the last 18 months after July 6, 2020.
reproduction of A-share “seesaw” effect:
tourism stocks broke out and covid-19 detection concept fell
Market data show that tourism stocks broke out this morning.
Many stocks such as Xi’An Qujiang Cultural Tourism Co.Ltd(600706) , Yunnan Tourism Co.Ltd(002059) , Utour Group Co.Ltd(002707) , China United Travel Co.Ltd(600358) rose by the limit, Anhui Jiuhuashan Tourism Development Co.Ltd(603199) , Caissa Tosun Development Co.Ltd(000796) followed the strength, and many tourism ETFs also rose sharply, with an intraday increase of more than 3%.
In terms of news, the State Council recently issued the “14th five year plan” for tourism development (hereinafter referred to as the “plan”).
The plan puts forward seven key tasks. First, we must persist in innovation driven development, deepen the “Internet plus tourism” and promote the development of intelligent tourism. Second, optimize the spatial layout of tourism, promote the coordinated development of urban and rural areas and regions, and build a number of tourism cities and characteristic tourism destinations; Third, build a scientific protection and utilization system, protect and inherit human resources and make good use of natural resources; Fourth, improve the supply system of tourism products, stimulate the vitality of the main body of the tourism market, promote “tourism +” and “+ tourism”, and form a new situation of multi industry integration and development; Fifth, expand the mass tourism consumption system, improve tourism consumption services, and better meet the people’s multi-level and diversified needs; Sixth, establish a modern tourism governance system, strengthen the construction of tourism credit system and promote civilized tourism; Seventh, improve the tourism open cooperation system, strengthen policy reserves and continue to promote tourism exchanges and cooperation.
The plan ensures the implementation from the aspects of strengthening organizational leadership, strengthening policy support, strengthening tourism theory and talent support, and requires all regions to formulate tourism development plans or specific implementation plans in combination with the actual situation of the region, clarify the division of work and implement work responsibilities. All departments shall, in accordance with the division of responsibilities, strengthen coordination and cooperation, clarify specific measures and work progress, and speed up the promotion.
At the same time of the outbreak of tourism stocks, covid-19 detected that concept stocks fell sharply, and many stocks fell by the limit, which had a strong “seesaw” effect with the performance of tourism stocks.
In the covid-19 detection concept, Asahi biology, Zhejiang Orient Gene Biotech Co.Ltd(688298) and other “20cm” stocks fell by the limit. Many stocks such as Hangzhou Biotest Biotech Co.Ltd(688767) , Beijing Hotgen Biotech Co.Ltd(688068) , Hangzhou Alltest Biotech Co.Ltd(688606) , Jiangsu Bioperfectus Technologies Co.Ltd(688399) fell by more than 10%.
Recently, bull stocks Andon Health Co.Ltd(002432) also closed the limit.
The company issued a stock trading risk warning announcement again last night. The announcement said that in the previous announcement, the company mentioned the epidemic prevention related plan issued by the U.S. government, as well as the relevant policies, procurement and distribution plans and conditions of covid-19 antigen household self-test kit products. Investors are reminded that the relevant information and procurement involved in the above contents are not only for the company. Investors are requested not to misunderstand the contents and mistakenly infer the changes it brings to the company’s performance.
Andon Health Co.Ltd(002432) also said that at present, the company’s share price is at an all-time high, which does not rule out the risk of falling in the future. I would like to remind investors that the company will strictly implement the relevant provisions on information disclosure of listed companies and timely fulfill the obligation of information disclosure. I also take this opportunity to remind investors again that there are many rumors on the Internet platform. Please refer to the information officially released by the company and do not calculate the company’s performance and future trend without basis. There are many factors affecting the stock price of the secondary market, and the development of the epidemic in the United States in the future is still uncertain. The sales of kit products are affected by many factors. Investors are invited to pay attention to investment risks and invest rationally.
On the news, on January 20, the Geneva pharmaceutical patent pool announced that it had signed an agreement with 27 generic pharmaceutical enterprises to produce molnupiravir, an oral covid-19 antiviral drug, which will promote patients around the world to use this covid-19 oral drug at an acceptable burden. Among them, there are 5 enterprises eligible for imitation in China, including Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Langhua pharmaceutical, Longze pharmaceutical, Brightgene Bio-Medical Technology Co.Ltd(688166) , and Desano pharmaceutical.
Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) A shares rose once this morning, and Brightgene Bio-Medical Technology Co.Ltd(688166) was “20 cm” in the morning.
“northeast yaomao” fell by the limit for three consecutive times
After the share price fell to the limit on January 19 and January 20, on the morning of January 21, Changchun High And New Technology Industries (Group) Inc(000661) known as “northeast medicine grass” fell to the limit again.
On January 19, Guangdong Pharmaceutical Trading Center issued the notice on the centralized procurement document of diclofenac and other drugs of Guangdong Alliance (hereinafter referred to as the document), and 276 drugs were included in the procurement list, including several recombinant human growth hormone.
Changchun High And New Technology Industries (Group) Inc(000661) when replying to investors’ questions in Shenzhen Stock Exchange interactive easy yesterday, the company continued to pay attention to policy changes. At present, the bidding process for centralized drug procurement has not been officially started, and the specific impact will also depend on the actual participation in bidding, winning results, winning prices, etc. the follow-up matters and the impact on the company are still uncertain, At present, there is no expectation that it will have a serious impact on the company’s operating performance. The company will actively pay attention to the follow-up progress, carefully study the provisions of relevant documents and reasonably formulate the implementation plan.
In the process of falling the limit in the previous two days, Changchun High And New Technology Industries (Group) Inc(000661) were listed on the dragon and tiger list of Shenzhen Stock Exchange. The dragon and tiger list data show that more institutional seats are sold. For example, in the dragon and tiger list on January 20, four seats showed net sales, with a net sales amount of more than 100 million yuan.
It is worth noting that Changchun High And New Technology Industries (Group) Inc(000661) announced at noon today that some directors, supervisors and senior managers increased their holdings of the company’s shares, as well as the repurchase results and share change announcement.
According to the announcement of the company, Changchun High And New Technology Industries (Group) Inc(000661) several directors and supervisors increased their holdings of the company’s shares on January 21, 2022 (Note: calculated according to the disclosure time, that is, this morning). The increased holdings include Ma Ji, chairman, Jiang Yuntao, director and general manager, Ye Peng, director and executive deputy general manager, Wang Zhigang, director and deputy general manager, Xie Bing, chairman of the board of supervisors, Zhao Shuping, supervisor, Li Xiufeng, deputy general manager, Zhu Xinggong, deputy general manager and chief financial officer, and Zhang Deshen, Secretary of the board of directors.
For the purpose of increasing holdings, the announcement said that it is the recognition of the company’s long-term value and confidence in the company’s future development. The funds for the above-mentioned persons to increase their shares are self raised funds. This increase is the personal behavior of the company’s directors, supervisors and senior managers.
Hong Kong stocks adjusted slightly in the morning
After yesterday’s sharp rise, Hong Kong stocks adjusted this morning. The Hang Seng Index fell less than 1%.
Hang Seng technology index fell slightly, with an intraday decline of more than 1%.
Ruisheng technology and Alibaba Hong Kong stocks both fell more than 5%. Netease, Shunyu optical technology, Ping’an good doctor and auto home led the decline.
However, overall, Hong Kong stocks fell little this morning.
In the past Thursday, Hong Kong stocks had a rare surge in the past year. The Hang Seng Index rose as high as 3.42% throughout the day, the largest one-day increase in the last 18 months after July 6, 2020.
